Indication name: Pro-opiomelanocortin
(POMC)
"Pro-opiomelanocortin (POMC) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020
To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy,
Japan & China).
Pro-opiomelanocortin
(POMC)
deficiency is a form of monogenic obesity resulting in severe early-onset
obesity, adrenal insufficiency, red hair and pale skin. POMC deficiency is
caused by mutations in the POMC gene, which provides instructions for making
the proopiomelanocortin protein. The condition is inherited in an autosomal
recessive pattern
Epidemiology- POMC deficiency is a rare
condition; approximately 50 cases have been reported in the medical literature.
Competitive landscape of
Pro-opiomelanocortin (POMC) includes country specific approved as well as
pipeline therapies. Any asset/ product specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs insights of Pro-opiomelanocortin (POMC)
across 8 MM market from center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm and Unmet
needs.
Pro-opiomelanocortin (POMC) Market Forecast:
Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing,
Market Event and Product Event, Country specific Forecast Model, Market uptake
and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden
and pricing scenario, Summary and Insights.
S. No
Asset Company Stage
1
Setmelanotide Rhythm
Pharmaceuticals, Inc. Phase 3
2
Adrenocorticotropic Hormone
Mallinckrodt Phase 1
3 LCI699 Novartis Pharmaceuticals Phase 2"
No comments:
Post a Comment